TNF-alpha Inhibitors in Systemic Lupus Erythematosus. A Case Report and a Systematic Literature Review

Mod Rheumatol. 2015 Jul;25(4):642-5. doi: 10.3109/14397595.2013.844306. Epub 2013 Nov 4.


Joint involvement is a common manifestation of systemic lupus erythematosus (SLE) and is described as a non-erosive mild synovitis. However some SLE patients may present a more severe joint involvement requiring aggressive therapy. We describe the case of a SLE patient with a severe arthritis unresponsive to methotrexate, successfully treated with anti-TNF-alpha drug as induction therapy and we report the results of a systematic literature review on the use of TNF-alpha inhibitors in SLE.

Keywords: Anti-TNF therapy; Joint involvement; Systemic lupus erythematosus; treatment targets.

Publication types

  • Case Reports
  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Certolizumab Pegol / therapeutic use*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lupus Erythematosus, Systemic / drug therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / metabolism


  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Certolizumab Pegol